Cas9 Stable Cell Line - REC1

The REC1-Cas9 stable cell line is a robust genetic model derived from the human REC1 mantle cell lymphoma cell line, genetically engineered to constitutively express the Cas9 nuclease. REC1 is a suspension B cell line derived from the lymph nodes of a 57-year-old male patient with mantle cell lymphoma (MCL). Its cytogenetic signature is the t(11;14)(q13;q32) translocation, typically exhibiting a mature B cell phenotype (CD19+, CD20+, but often CD5-). Integrating Cas9 into this context provides a highly standardized and efficient platform for CRISPR-mediated gene editing in the context of aggressive lymphoma. This system ensures stable and efficient editing, making it ideal for high-throughput functional genomics studies aimed at elucidating molecular pathways in mantle cell lymphoma and identifying novel therapeutic targets.

The primary applications of the REC1-Cas9 stable cell line are identifying genetic drivers of lymphoma progression and screening for novel drug targets. Researchers used this cell line for CRISPR screening to discover genes involved in cell cycle regulation, apoptosis, and resistance mechanisms to targeted therapies and chemotherapy drugs. The REC1-Cas9 cell line is particularly suitable for constructing homologous clones with specific gene knockouts, enabling scientists to study the roles of B cell-specific oncogenes and tumor suppressor genes in disease progression. Furthermore, it can serve as a reliable platform for evaluating the efficacy of novel targeted therapies and studying the molecular pathways of B cells in response to various stimuli.